Loading...

DXCM DEXCOM INC Legal Disputes 8-K Filing

DXCM

DXCM

DEXCOM INC

(DXCM)

2024 8-K

Show Summary

Summary

Equity Offerings

Board Appointment

FDA Warning Letter

Financial Results

Financial Results

Patent Settlement

Financial Results

Financial Results and Share...

Annual Meeting of Stockholders

Financial Results Announcement

Termination of Warrants

Financial Results Announcement

Preliminary Financial Results

Share Repurchase Agreement

Financial Results Announcement

Share Repurchase Program

Earnings Reports

Regulation FD Disclosure

Severance Plan Amendments

Sale of Convertible Senior ...

Earnings Reports

Financial Results Announcement

Financial Results

External Links:

Dexcom and Abbott have settled their patent litigation by entering into a cross-licensing agreement that allows both companies to use each other's patents without paying royalties until December 2034.

AI Assistant

DEXCOM INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.